Noteworthy - Pharmaceutical Executive

ADVERTISEMENT

Noteworthy

Pfizer's Quality by Design Approach to Trial Management

April 1, 2013

Improving the quality of clinical trials is a major strategic activity for Big Pharma, one where efficient management of a demanding set of regulatory requirements can have a positive impact on the bottom line.

Patients on the Picket Line

March 1, 2013

Do terminally ill patients have a right to try unapproved, investigational drugs? Ben Comer reports.

China and the Emerging Markets Challenge

March 1, 2013

Chinese policies are to pose new opportunities and challenges for Big Pharma companies active in the country.

Right Board for the Brand

March 1, 2013

Pharm Exec's 35-member Editorial Advisory Board met last month to discuss a range of topics, including the influence of other business sectors on pharma's global strategy.

Less Selling, More Time

March 1, 2013

What can happen when reps focus on the physician-patient conversation? Al Topin reports.

Brand of the Year: Januvia

March 1, 2013

In 2012, Merck's diabetes franchise became the highest-selling product family in its 122-year history.

Rethinking Product Lifecycle Management

February 1, 2013

"Drug Life Optimization" can wrest more value through strategies that build a drug's brand franchise through its entire lifespan, according to Stan Bernard.

Oncology: Pathways to Progress

February 1, 2013

Pharm Exec recently convened a cross-section of industry experts to review current and pending efforts to turn great science into good oncology practice.

In Cancer, Process Drives Progress

February 1, 2013

Today's most important public health story is the advance in our understanding of the biology of cancer, writes Pharm Exec Editor-in-Chief William Looney.

ADVERTISEMENT

Click here